Physician profile
Chong S So
NPI 1972561231
$9,291.70
in general payments reported to CMS, 2019-2025
33 companies · $1,032 in 2025
The $1,032 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,570 · 2020: $1,367 · 2021: $870 · 2022: $607 · 2023: $2,036 · 2024: $1,810 · 2025: $1,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,877.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,265.19 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,157.17 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $975.53 | 2019-2025 | Stiolto Respimat, Jardiance |
| Glaxosmithkline, LLC. | $877.63 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $654.77 | 2019-2025 | |
| Gilead Sciences, INC. | $582.40 | 2019-2025 | Descovy |
| Bayer Healthcare Pharmaceuticals INC. | $532.78 | 2023-2025 | |
| Lilly USA, LLC | $521.81 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $349.16 | 2019-2024 | Wegovy, Rybelsus, Saxenda |
| Otsuka America Pharmaceutical, INC. | $310.31 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $250.44 | 2019-2025 | Xifaxan |
| Philips North America LLC | $205.10 | 2022-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Astellas Pharma US INC | $192.64 | 2019-2024 | Myrbetriq, Veozah |
| Phathom Pharmaceuticals, INC. | $181.26 | 2024 | Voquezna |
| Lundbeck LLC | $161.19 | 2024-2025 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $134.07 | 2019-2020 | |
| Exact Sciences Corporation | $128.99 | 2023-2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $126.67 | 2019-2021 | |
| Amarin Pharma, INC. | $107.23 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $81.32 | 2021-2023 | |
| Amgen INC. | $76.41 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $62.37 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.76 | 2020-2023 | Trintellix |
| Bausch Health US, LLC | $52.39 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $40.64 | 2020-2023 | Eliquis |
| Abbott Laboratories | $37.64 | 2019 | |
| Verona Pharma, INC. | $31.47 | 2025 | Ohtuvayre |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.10 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $25.21 | 2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $21.97 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $20.93 | 2024 | Xarelto |
| Shire North American Group INC | $20.71 | 2019 | |
| Tris Pharma INC | $14.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chong So listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.